Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Tilray Brands, Inc. TLRY

Alternate Symbol(s):  T.TLRY

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis business, Distribution business, Beverage alcohol business and Wellness business. The Cannabis business segment is engaged in the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. The Distribution business segment is focused on the purchase and resale of pharmaceutical products to customers. The Beverage alcohol business segment is engaged in the production, marketing and sale of beverage and beverage alcohol products. The Wellness business segment includes hemp foods and hemp-based cannabidiol (CBD) consumer products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Bake Sale, XMG, Mollo, and others.


NDAQ:TLRY - Post by User

Post by mystique1on Jan 08, 2022 9:17pm
829 Views
Post# 34296977

From. Bloomberg Canada Cannabis. January 8/22

From. Bloomberg Canada Cannabis. January 8/22
Analyst Call of the Week - What to expect when you're expecting Tilray's Q2
 

Canadian cannabis giant Tilray reports its fiscal second quarter results before markets open on Monday. Analysts expect the company to report US$164 million in revenue - an annual jump of 191 per cent - and US$11.3 million in adjusted EBITDA. However, Tilray's sales gains don't reflect the market share declines that the company has experienced, which may now hover at around nine per cent in Canada's largest provinces, according to BMO Capital Markets Analyst Tamy Chen.

She believes Tilray lost share to other players due to a combination of smaller producers supplying more premium flower to the market and deep discounting in the bulk segment. Alliance Global Partners also highlights how the resurgence of COVID and return of lockdowns in Ontario will likely see Tilray's market share fall even lower beyond its fiscal second quarter, according to Hifyre sales data. 

Cantor Fitzgerald's Pablo Zuanic points out that less than half of Tilray's revenue (42 per cent) is derived from its cannabis operations, and sees industry data showing the company's recreational pot sales down 16 per cent from its first quarter. Despite that, he expects Tilray's gross margins to remain stable or even up slightly in its second quarter.

""
Analyst Call of the Week - What to expect when you're expecting Tilray's Q2
 

Canadian cannabis giant Tilray reports its fiscal second quarter results before markets open on Monday. Analysts expect the company to report US$164 million in revenue - an annual jump of 191 per cent - and US$11.3 million in adjusted EBITDA. However, Tilray's sales gains don't reflect the market share declines that the company has experienced, which may now hover at around nine per cent in Canada's largest provinces, according to BMO Capital Markets Analyst Tamy Chen.

She believes Tilray lost share to other players due to a combination of smaller producers supplying more premium flower to the market and deep discounting in the bulk segment. Alliance Global Partners also highlights how the resurgence of COVID and return of lockdowns in Ontario will likely see Tilray's market share fall even lower beyond its fiscal second quarter, according to Hifyre sales data. 

Cantor Fitzgerald's Pablo Zuanic points out that less than half of Tilray's revenue (42 per cent) is derived from its cannabis operations, and sees industry data showing the company's recreational pot sales down 16 per cent from its first quarter. Despite that, he expects Tilray's gross margins to remain stable or even up slightly in its second quarter.
"""


<< Previous
Bullboard Posts
Next >>